The most satisfying translational example of this process has been in the case of CML, in which the t(9;22) translocation and the consequent enhanced tyrosine kinase activity of BCR-ABL can be effectively inhibited by imatinib. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.